ghmds | 20783

MDS Panel Mutations (bone marrow)

Keywords:

ANKRD26

ASXL1

BCOR

BCORL1

BRAF

CALR

CBL

CEBPA

CSF3R

DDX41

DNMT3A

ETV6

EZH2

FLT3

GATA1

GATA2

HRAS

IDH1

IDH2

IKZF1

JAK2

KIT

KRAS

MDS

MPL

Myelodysplastic neoplasms

Myelodysplastic syndrome NGS

NF1

NGS

NPM1

NRAS

Next Generation Sequencing

PHF6

PRPF8

PTPN11

RB1

RUNX1

SETBP1

SF3B1

SF3B1 mutation

SH2B3

SMC1A

SMC3

SRSF2

STAG2

STAT3

TET2

TP53

U2AF1

UBA1

WT1

ZRSR2

Status

Material

Bone marrow blood

EDTA-Tube bone marrow (6)

Hint

ANKRD26, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ETV6, EZH2, FLT3 (ITD, TKD), GATA1, GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PHF6, PRPF8, PTPN11, RB1, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, TET2, TP53, U2AF1, UBA1, WT1, ZRSR2 | There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. | Since in rare cases there may also be indications of hereditary changes, the GUMG (Federal Law on Genetic Testing in Humans) provides for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent).

Min. volume

4 mL

Stability

1 day / 18-25°C; 4 days / 2-8°C

Duration

5 days

Frequency

2 x per week

Method

Next Generation Sequencing